Insights
Search Results
Client Highlights
4.08.26
Wilson Sonsini Advises Renovare Therapeutics on Company Launch and Collaboration with CU Boulder
On April 6, 2026, Renovare Therapeutics, a privately held biotechnology company pioneering regenerative therapeutics for osteoarthritis, announced its formal launch from stealth mode and collaboration with University of Colorado (CU) Boulder. Wilson Sonsini Goodrich & Rosati advised Renovare Therapeutics on the transaction.
Client Highlights
4.01.26
Wilson Sonsini Advises Ambrosia Biosciences on $100 Million Oversubscribed Series B Financing
On March 31, 2026, Ambrosia Biosciences, Inc., a privately held drug discovery company, announced a $100 million oversubscribed Series B preferred stock financing. The round was co-led by new investors Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital. Existing investors BVF Partners and Boulder Ventures also participated, and were joined by additional new investors. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.
Case Studies
2.24.26
How Wilson Sonsini Helped Foresight Diagnostics with Its Growth, Scale-Up, and Acquisition
Foresight Diagnostics is a leading cancer diagnostics company founded in 2020 and spun out of Stanford University. Foresight has developed a novel liquid biopsy testing platform for the measurement of minimal residual disease that is significantly more sensitive than existing tests. Its technology, called PhasED-SeqTM, is based on a simple blood draw and next-generation sequencing. It is broadly applicable to a variety of cancers, and its ability to detect circulating tumor DNA at levels of 0.0001 percent (or one part-per-million) has the potential to provide actionable information to physicians and biopharmaceutical companies, thus enabling the development of a more proactive and personalized treatment approach.
Client Highlights
12.08.25
Wilson Sonsini Advises Foresight Diagnostics on Acquisition by Natera
On December 5, 2025, Natera, Inc., a global leader in cell-free DNA and precision medicine, and Foresight Diagnostics, a leader in ultrasensitive molecular residual disease (MRD) detection, announced that Natera has completed its acquisition of Foresight in an all-stock transaction consisting of a $275 million upfront payment with an additional $175 million in earnouts tied to the achievement of revenue- and reimbursement-based milestones. Wilson Sonsini Goodrich & Rosati advised Foresight on the transaction.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
The transaction combines Natera’s leading commercial and operational infrastructure for the delivery of personalized MRD testing with Foresight’s unique phased variant technology and leadership in lymphoma. It builds on Natera’s broad intellectual property portfolio for tumor-informed and personalized MRD products including in phased variants, and promises to accelerate MRD adoption in lymphoma and other solid tumor types.
Client Highlights
12.10.24
Wilson Sonsini Advises Ambrosia Biosciences on $25 Million Series A
On December 10, 2024, Ambrosia Biosciences, a drug discovery company developing orally delivered, small molecule-based therapies for obesity and other metabolic disorders, announced the successful second closing of its Series A financing. This closing was led by Merck with additional participation from existing investors BVF Partners and Boulder Ventures. Wilson Sonsini Goodrich & Rosati advised Ambrosia Biosciences on the transaction.
Client Highlights
4.28.23
Wilson Sonsini Advises Foresight Diagnostics on $58.75 Million Series B
On April 27, 2023, Foresight Diagnostics, Inc, a leading developer of ultrasensitive cancer detection tests, announced the close of an oversubscribed Series B financing round of $58.75 million. The financing was led by Foresite Capital, with participation by Civilization Ventures, Bluebird Ventures, Pear Ventures, Agent Capital, Stanford University, and The University of Colorado Healthcare Innovation Fund. Wilson Sonsini Goodrich & Rosati advised Foresight on corporate, IP, licensing, and business advisory matters related to the transaction.
Client Highlights
10.11.22
Wilson Sonsini Advises Electra on $85 Million Fundraise
On October 6, 2022, Electra, a green iron company, announced it raised $85 million to produce Low-Temperature Iron (LTI) from commercial and low-grade ores using zero-carbon intermittent electricity. The company's backers include Bill Gates-founded Breakthrough Energy Ventures, Amazon, BHP Ventures, Temasek, S2G Ventures, Capricorn Investment Group, Lowercarbon Capital, Valor Equity Partners, Baruch Future Ventures, and others.
Press Releases
6.14.22
Wilson Sonsini Continues to Build in Boulder as Brent Fassett Joins Corporate Practice
Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, and growth enterprises worldwide, announced today that Brent Fassett has joined the firm’s corporate practice as a partner in the Boulder, Colorado, office. His addition bolsters Wilson Sonsini’s private and public company and transactional experience in the life sciences sector. Fassett is the first lateral partner to join the Boulder office since the firm announced plans to open a location in Colorado.